Klasinc Romana, Rieger Armin, Presterl Elisabeth, Wrba Thomas, Diab-Elschahawi Magda
Department of Infection Control and Hospital Epidemiology, Medical University of Vienna, Vienna, Austria.
Department of Dermatology, Division of Immundermatology and Infectious Diseases of the Skin, Medical University of Vienna, Vienna, Austria.
Infect Disord Drug Targets. 2018;18(3):199-206. doi: 10.2174/1871526518666180405153616.
There is limited published data concerning the recent epidemiology of urinary tract infections (UTI) in HIV-patients, thus we analysed independent risk factors for UTI in HIV positive individuals and antimicrobial resistance rates of E. coli to antimicrobial agents commonly used in UTI. To determine the prevalence of symptomatic urinary tract infections (UTI) in HIV-patients, we performed a retrospective case-control study.
We included 313 HIV-patients, 101 with UTI and 212 age and gendermatched controls, attending the HIV outpatient clinic at the Vienna University Hospital (VUH) over a period from January 2011 to September 2016. The patients' specific data was gathered from the electronic database of the VUH. The statistical analysis was performed using SPSS Software Version 20.0.
HIV infected individuals with CD4 count >200 cells/mm3 were less likely than HIV infected individuals with CD4 count <200 cells/mm3 to experience UTI (OR 0.811, 95% CI 0.712-0.923 vs. OR 2.555, 95% CI 1.553 - 4.205, respectively). The in vitro resistance rate of E. coli to antimicrobial agents was as follows: ciprofloxacin (41%), mecillinam (20.5%), trimethoprim (61%), ampicillin (67%), ampicillin/ clavulanic acid (23%), cefuroxime (17%), nitrofurantoin (2%), amikacin (0%) and gentamicin (9.5%).
Immunological status (CD4 count) is an important parameter for risk assessment of UTIs in HIV-patients. The increased resistance rate of E. coli to commonly used antimicrobial agents needs to be considered when it comes to the management of UTI, additionally, surveillance strategies should be implemented in HIV-patients.
关于HIV患者尿路感染(UTI)近期流行病学的已发表数据有限,因此我们分析了HIV阳性个体发生UTI的独立危险因素以及大肠杆菌对UTI常用抗菌药物的耐药率。为确定HIV患者中症状性尿路感染(UTI)的患病率,我们进行了一项回顾性病例对照研究。
我们纳入了2011年1月至2016年9月期间在维也纳大学医院(VUH)HIV门诊就诊的313例HIV患者,其中101例患有UTI,212例为年龄和性别匹配的对照。患者的具体数据从VUH的电子数据库中收集。使用SPSS软件20.0版进行统计分析。
CD4计数>200个细胞/mm3的HIV感染者发生UTI的可能性低于CD4计数<200个细胞/mm3的HIV感染者(OR分别为0.811,95%CI 0.712 - 0.923与OR 2.555,95%CI 1.553 - 4.205)。大肠杆菌对抗菌药物的体外耐药率如下:环丙沙星(41%)、美西林(20.5%)、甲氧苄啶(61%)、氨苄西林(67%)、氨苄西林/克拉维酸(23%)、头孢呋辛(17%)、呋喃妥因(2%)、阿米卡星(0%)和庆大霉素(9.